Form 4: Halozyme Therapeutics CFO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Nicole LaBrosse, CFO of Halozyme Therapeutics, executed stock options and sold shares between June 26 and June 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Nicole LaBrosse, the SVP and CFO of Halozyme Therapeutics, exercised options to purchase common stock at a price of $22.50 per share on June 26, 27 and 28, 2024.
- Concurrently, LaBrosse sold 10,000 shares of common stock on each of those days, at weighted average prices ranging from $51.82 to $52.04.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on March 22, 2024.
- Following these transactions, LaBrosse directly owns 15,480 shares of Halozyme Therapeutics common stock.
- She also holds options to purchase 5,000 shares of common stock, which were granted on July 1, 2015, and vested over time.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by a company executive under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan suggests that these transactions were pre-planned and not based on any inside information at the time of the trades.
Key Dates
| Date | Description |
|---|---|
| 07/01/2015 | Date options were granted |
| 03/22/2024 | Date Rule 10b5-1 trading plan was adopted |
| 06/26/2024 | Date of first reported transaction (option exercise and stock sale) |
| 06/27/2024 | Date of second reported transaction (option exercise and stock sale) |
| 06/28/2024 | Date of third reported transaction (option exercise and stock sale) |
| 07/01/2025 | Expiration date of options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.